SCHEMBL15021080

SCHEMBL15021080

CCCCCCC(CCCC)C(=O)Nc1cc(C(=O)OC)cc(C(=O)OC)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.68
HSD17B10 Q99714 2/20 0.58
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.48
ERAP2 Q6P179 2/20 0.44
LNPEP Q9UIQ6 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC8 Q9BY41 5/20 0.43
HDAC3 O15379 3/20 0.43
HDAC6 Q9UBN7 3/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1525510 0.99 LMNA (0.69) LMNAHSD17B10KDM4EALDH1A1ERAP2
SCHEMBL1525416 0.96 LMNA (0.65) LMNAHSD17B10KDM4EALDH1A1ERAP2
SCHEMBL15020945 0.86 MEN1 (0.61) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL1525323 0.85 MEN1 (0.63) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL8616893 0.83 MEN1 (0.50) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL1820404 0.83 LMNA (0.48) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL1525705 0.82 MEN1 (0.68) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL8616897 0.81 MEN1 (0.50) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL18744145 0.79 LMNA (0.46) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL11309272 0.78 HSD17B10 (0.50) LMNAHSD17B10KDM4EALDH1A1ERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9623345-B2 Phase selective gelation with alkylated aromatic acid compounds XEROX CORPORATION (US) 2017-04-18 US disclosed
US-9067878-B2 Organogel compositions comprising alkylated aromatic acids XEROX CORPORATION (US) 2015-06-30 US disclosed
US-20130158135-A1 Organogel Compositions Comprising Alkylated Aromatic Acids NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2013-06-20 US disclosed
US-20130153508-A1 Phase Selective Gelation With Alkylated Aromatic Acid Compounds NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158135-A1 Organogel Compositions Comprising Alkylated Aromatic Acids F12, AHR, RXRG LMNA 1629/4885HSD17B10 1579/4885KDM4E 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.